This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD).

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

This brochure informs patients about buprenorphine and medication-assisted treatment for opioid use disorder. It describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.

This manual provides guidelines for the operation of opioid treatment programs. It covers patient assessment, treatment planning, and recovery care. The manual also offers guidance for medication-assisted treatment for methadone and buprenorphine, and overdose and relapse prevention.

This guide highlights the use of medication-assisted treatment (MAT) for opioid use disorder in drug courts. It reviews effective medications, including methadone, buprenorphine, and naltrexone. The guide also provides strategies to increase the use of MAT in drug court programs.

This manual serves as a quick reference guide for clinicians treating chronic pain in adults living with a history of substance use. It covers patient assessment and treatment, and provides an algorithm for managing chronic pain, as well as a summary of non-opioid analgesics.

This quick guide summarizes guidelines for clinicians treating chronic pain in adults living with a history of substance misuse. It covers patient assessment, chronic pain management, managing addiction risk in patients treated with opioids, and patient education.